Trial · NCT00744055

Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).

NCT00744055, Phase 3, Completed, Yale University; results first posted 2016-01-18

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD). Trials, record NCT00744055. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00744055

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).
NCT number: NCT00744055
Status: Completed
Phases: Phase 3
Enrollment: 96 participants, actual
Lead sponsor: Yale University
Conditions: Alcohol Dependence, Stress Disorders, Post-Traumatic
Interventions: Prazosin, Placebo
First posted: 2008-08-29
Last updated: 2020-03-19
Results first posted: 2016-01-18

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Drinking Days	12 weeks	Using the Timeline Follow Back method, a calendar method for assessing drug and alcohol use
Primary	Clinician-Administered PTSD Scale	12 weeks	Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). A higher score is associated with higher severity of PTSD. The score is interpreted as follows: 0-19=Asymptomatic/few symptoms 20-39=Sub-threshold/mild PTSD 40-59=Threshold PTSD/moderate 60-79=Severe PTSD \>80=Extreme PTSD

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Drinking Days	12 weeks		days	MEAN
PRIMARY	Clinician-Administered PTSD Scale	12 weeks		units on a scale	MEAN

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Drinking Days	Prazosin	11.04	Standard Deviation 18.86	days
Number of Drinking Days	Placebo	9.21	Standard Deviation 16.64	days
Clinician-Administered PTSD Scale	Prazosin	37.94	Standard Deviation 37.62	units on a scale
Clinician-Administered PTSD Scale	Placebo	37.93	Standard Deviation 41.13	units on a scale

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Prazosin	50
Overall Study	STARTED	Placebo	46
Overall Study	COMPLETED	Prazosin	43
Overall Study	COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	Prazosin	7
Overall Study	NOT COMPLETED	Placebo	14

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Alcohol Relapse	Psychiatric disorders	Prazosin	5	50
other	Alcohol Relapse	Psychiatric disorders	Placebo	7	46
other	Homocidal Ideation	Psychiatric disorders	Prazosin	0	50
other	Homocidal Ideation	Psychiatric disorders	Placebo	1	46
other	Partial thrombus	Vascular disorders	Prazosin	1	50
other	Partial thrombus	Vascular disorders	Placebo	0	46
other	Chest Pain	Respiratory, thoracic and mediastinal disorders	Prazosin	1	50
other	Chest Pain	Respiratory, thoracic and mediastinal disorders	Placebo	0	46
other	Appendicitis	Gastrointestinal disorders	Prazosin	1	50
other	Appendicitis	Gastrointestinal disorders	Placebo	0	46

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Prazosin
Total, all-cause mortality	Placebo
Total, other adverse events	Prazosin	11	50
Total, other adverse events	Placebo	8	46
Total, serious adverse events	Prazosin	0	50
Total, serious adverse events	Placebo	0	46

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
29461925	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons1

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison
Prazosin vs Placebo: serious adverse events

Source Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00744055

GET https://conductscience.org/api/trials/v1/NCT00744055/registered

API reference For AI assistants